|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Center for Human Genetics, the Department of
Pathology, the Laboratory of Experimental Hematology, Catholic
University of Leuven, Belgium.
Single-cell polymerase chain reaction (PCR) has been used as a tool
to demonstrate clonality and B-cell origin of Reed-Sternberg (RS) cells
in Hodgkin disease (HD). An analogous approach was used to investigate
genomic imbalances in a (cyto)genetically poorly characterized
subentity: lymphocyte predominance Hodgkin disease (LPHD).
Nineteen cases of LPHD were selected for a comparative genomic
hybridization (CGH) study. CGH was performed with degenerate oligonucleotide primed-PCR (DOP-PCR)-amplified DNA from 4-5 microdissected CD20+ malignant cells. All analyzed cases
revealed a high number of genomic imbalances (average 10.8 per case),
involving all chromosomes but the excluded 19, 22, and Y, indicating a
high complexity of LPHD. The majority of detected aberrations were
recurrent. Gain of 1, 2q, 3, 4q, 5q, 6, 8q, 11q, 12q, and X, and loss
of chromosome 17 were identified in 36.8% to 68.4% of the analyzed
cases. Some of them have also been found in non-Hodgkin lymphoma (NHL),
and possibly represent secondary changes associated with disease
progression. Gain of 2q, 4q, 5q, 6, 11q, however, are much more rarely
observed in NHL and could be more specifically associated with LPHD.
Particularly interesting is a frequent overrepresentation of chromosome
arm 6q, a region usually deleted in NHL. Rearrangement of the
BCL6 gene (3q27) demonstrated by cytogenetics and
fluorescence in situ hybridization in 2 cases in this study suggests
its contribution in pathogenesis of LPHD. In conclusion, the data show
a consistent occurrence of genomic alterations in LPHD and highlight
genomic regions that might be relevant for development and/or
progression of this lymphoma entity.
(Blood. 2001;97:1845-1853) Hodgkin disease (HD), one of the most common
malignant lymphomas in the western world, was first described by Thomas
Hodgkin in 1832. The characteristic morphologic feature of HD is the
cellular composition of the tumor tissue containing a small number
(approximately 0.1% to 1%) of neoplastic Reed-Sternberg (RS) cells
and a major population of nonneoplastic lymphocytes, histiocytes,
neutrophils, fibroblasts, eosinophils, and plasma cells. On the basis
of tumor cell morphology, immunophenotype, and the composition of the
cellular background, 2 separate biologic entities, namely, lymphocyte
predominance Hodgkin disease (LPHD) (or nodular paragranuloma) and
classical HD have been recognized in the Revised European-American
Lymphoma (REAL) classification.1 LPHD accounts for 5% of
all HD cases. Typically, patients are 25- to 45-year-old men and
usually present at an early clinical stage. More than 90% of patients
with LPHD have a complete response to therapy, although recurrences
frequently occur. In LPHD, a particular variant of RS cells, the
"popcorn" or lymphocytic and histiocytic (L&H) cells, is found. In
contrast to RS cells of classical HD, "popcorn" cells lack the
expression of CD30 and CD15 but express CD45 and CD20. The expression
of these markers and presence of nodular structures closely resembling lymphoid B follicles have suggested that "popcorn" cells represent neoplastic germinal center B cells.2-4
Because of the very low frequency of RS and "popcorn" cells
in the tumor tissue and the lack of suitable methods for their purification and analysis, clonality and lineage derivation of neoplastic cells in HD have remained uncertain until recently. As soon
as single-cell polymerase chain reaction (PCR)-based methods had been
developed, clonal Ig rearrangement and consistent occurrence of somatic mutations within the variable-regions of Ig genes
amplified from isolated RS and "popcorn" cells have been
demonstrated in the majority of analyzed cases. These findings
indicated a clonal germinal-center (GC) or post-GC B-cell origin
of LPHD as well as of classical HD.5-11 On the other
hand, polyclonal Ig rearrangements found in some HD
cases12-14 led to the hypothesis of a sequential poly-/oligo-/monoclonal origin of HD, a matter that is still under discussion.15-16
Despite recent progress in HD research, genetic and molecular
data are only scarcely available. There are intrinsic technical problems in obtaining metaphase chromosomes in HD (low number of RS
cells, low proliferation index, infiltration of reactive cells), and
therefore no more than 200 HD cases with abnormal karyotypes have been
reported until now (reviewed by Falzetti et al17
and Pedersen et al18). Despite the detection of recurrent chromosomal aberrations also demonstrated by interphase fluorescence in
situ hybridization (FISH), by FISH combined with CD30 immunophenotyping of RS cells,19-21 and by comparative genomic hybridization
(CGH),22,23 so far no specific cytogenetic marker(s) could
be identified. Single RS-cell PCR analysis of CMYC,
BCL2, and BCL1 suggested that these non-Hodgkin
lymphoma (NHL)-specific genes are not involved in the pathogenesis of
HD.24,25
Even less is known about genetic and molecular aberrations in
the LP subtype of HD. To the best of our knowledge, only 9 LPHD cases
with clonal chromosomal abnormalities have been
reported.17,18,26-31 Five of these revealed hyperdiploid
karyotypes and most showed complex chromosomal aberrations.
In this study, we investigated a series of 19 LPHD cases by
using CGH. Because of the low number of neoplastic cells in LPHD, the
analysis was performed on degenerate oligonucleotide primed-PCR (DOP-PCR)-amplified DNA obtained from microdissected CD20+
"popcorn" cells. By using this approach, we found genomic
imbalances in all cases, revealing the occurrence of recurrent
chromosomal abnormalities in LPHD.
Patients
Conventional cytogenetics
Microdissection of tumor cells Frozen sections of 8 µM were cut. For immunodetection, an alkaline phosphatase-conjugated ABC complex (Dakopatts, Glostrup, Denmark) was used subsequent to the application of the CD20 (L26) (Dako, Glostrup, Denmark) antibody. Slides were stained and pretreated for 60 minutes at 37°C with Collagenase H (1%, type II, Sigma-Aldrich, St Louis, MO) dissolved in phosphate-buffered saline (PBS) (pH 7.4). Single CD20+ L&H cells were microdissected and harvested under a microscope (Leica, Wetzlar, Germany). The manipulation procedures were performed with 2 3-dimensional hydraulic micromanipulators equipped with a joystick (Narishige, Tokyo, Japan). Manipulation tools consisted of a reception pipette and a manipulation knife prepared from glass capillaries. CD20+ cells were mobilized with the help of the manipulation knife and aspirated into the reception pipette. Four to 5 microdissected cells were collected in a PCR tube and resuspended in 7 µL of solution (26 mM Tris HCl, pH 9.5; 6.5 mM MgCl2) containing 2.3 µg proteinase K. The cells were digested overnight at 37°C, followed by boiling for 10 minutes to inactivate proteinase K.DOP-PCR The DOP-PCR was used to universally amplify tumor DNA and total normal DNA in a thermal cycler. The protocol used was modified from Kuukasjarvi et al.33 Four cycles were carried out in a 10-µL reaction mixture by adding 0.2 mM of each dNTP, 1 µM UNI primer and 10 units Thermo Sequenase DNA polymerase (Amersham, Cleveland, OH), followed by 25 cycles in a 50-µL reaction volume (adding 1 mM Tris HCl pH 8.3, 5 mM KCl, 0.16 mM dNTPs, 2.5 mM MgCl2, 1.2 µM UNI primer, 2.5 units AmpliTaq Polymerase [LD, PerkinElmer, Branchburg, NJ]). The DOP-PCR product of each microdissected case and normal DNA were purified by using the QIAquick PCR purification kit (Qiagen, Hilden, Germany).Comparative genomic hybridization CGH was performed according to methods described by Kallioniemi et al34 with minor modifications. Briefly, tumor DNA (PCR product) and normal DNA (PCR product) were labeled with direct fluorochrome-conjugated nucleotides by nick-translation with fluorescein-12-dUTP (green) and lissamine-5-dUTP (red) (NEN Life Science Products, Boston, MA), respectively. The size of the nick-translated fragments ranged from 300 to 3000 base pairs (bp). Equal amounts (500 ng) of labeled tumor and normal DNA were denatured together with 15 µg COT-1 DNA (GIBCO/BRL, Gaithersburg, MD), dissolved in hybridization mix (50% deionized formamide, 2 × standard saline-sodium citrate buffer (SSC), 10% dextran sulfate), and cohybridized to a denatured slide with normal metaphase chromosomes. After 72 hours of hybridization at 37°C, washes were performed to a stringency of 0.1 × SSC at 60°C. The slides were counterstained with 4,6-diamidino-2-phenylindole (DAPI) (blue) for chromosome identification.The image analysis was performed using an epifluorescence microscope
(DMRB, Leica) and image analysis software (QUIPS, Vysis, Downers Grove,
IL). The ratio of fluorescein isothiocyanate/lissamine fluorescence
intensities was calculated along each individual chromosome. Ratio
values obtained from 10 metaphase spreads per case were averaged and
the resulting profile was blotted next to the ideogram. Heterochromatic
regions and the entire chromosome Y were excluded from analysis.
Chromosomes 19 and 22 results were excluded from the final calculation
because they are known to be critical in CGH.35 Because
chromosomes 19 and 22 abnormalities were not observed in our control
experiments, imbalances affecting these chromosomes found in some of
our patients are shown in brackets in Figure
1.
Control hybridization was performed with each CGH experiment and included hybridization of DNA from normal female on male chromosomes (overrepresentation of chromosome X being used as additional internal control). By direct labeling, ratios above 1.15 and below 0.85 were considered to represent chromosomal gains and losses, respectively. These cut-off values are based on our results from control experiments that used 4 to 20 microdissected cells (data not shown). Overrepresentations were considered as high-level amplifications when the fluorescence ratio values exceeded 2.0. The extension of imbalanced regions was assessed by comparison of the fluorescence ratio profiles with the corresponding regions in chromosome ideograms. Control experiments and fluorescence in situ hybridization To validate our approach (microdissection of 4 to 5 single "popcorn" cells, followed by DOP-PCR and CGH), various control experiments were performed.To check whether the amplification of DNA by DOP-PCR influences CGH results, we performed the following investigations: (1) CGH on DOP-PCR-amplified DNA from normal total DNA (8 tests), and (2) CGH using DOP-PCR-amplified DNA from a microdissected area containing 10 to 15 normal cells from reactive lymph node biopsy cohybridized with DOP-PCR-amplified total DNA (3 tests). In both instances, no genomic imbalances were detected, and the green-to-red fluorescence ratios were always in the normal range in all analyzed chromosome arms, confirming the homogeneous amplification of genomic DNA by DOP-PCR. To check whether CGH results obtained by using DOP-PCR-amplified tumor DNA are the same as CGH results obtained by using total tumor DNA (not amplified by PCR), 2 additional studies were performed. We selected 2 marginal zone B-cell lymphomas that were previously characterized by cytogenetics, conventional CGH, and FISH.36 In both cases, we microdissected small regions containing 10 to 15 neoplastic cells from frozen sections, amplified the tumor DNA as well as the normal DNA by DOP-PCR, and did CGH. The obtained CGH results were identical to the CGH results produced from total DNA (data not shown). The reliability of our approach was finally also tested by performing CGH on: (1) 2 sets of 4 to 5 "popcorn" cells microdissected from different regions of the same lymph node biopsy (case 9), (2) DNA from 5 as well as 20 cells microdissected from the same lymph node in case 18, and (3) 2 sets of "popcorn" cells coming from 2 consecutive lymph node biopsy specimens taken at time of the first and second relapse (4 years later) in the same LPHD patient (case 11a and 11b). In the 3 experiments, 2 identical profiles of genomic imbalances were detected. To confirm the CGH results, we performed FISH on frozen sections in 6 cases (1, 2, 4, 6, 9, and 10) with available frozen tissue. After CD20 immunostaining at least 20 CD20+ L&H cells were captured and positioned using a sensor control display (SCD) on a Zeiss Axioplan 2 (Zeiss, Jena, Germany) microscope. Sections were fixed as described by Weber-Matthiesen et al,19 and FISH was performed by using alpha-satellite probes for chromosomes 6 (D6Z1), 16 (D16Z1), and 17 (D17Z1) (all from Vysis, IL) and chromosomes 1 (puc 1.77), 3 (p3.5), and 7 (p7t1) (kindly provided by B. Beverloo, Rotterdam, The Netherlands). After FISH, the previously identified and captured CD20+ L&H cells were relocated and analyzed. Cases 9 and 14 with available cytogenetic fixed cells were analyzed by using cos B5-2 for the BCL6 gene (kindly provided by T. Miki, Japan), puc 1.77 for centromere 1, and D6Z1 for centromere 6 in case 9 and cos B5-2, WCP1, and WCP3 (Vysis) in case 14. Experiments were carried out by using a previously described protocol.37
Relevant clinical and cytogenetic data of the 19 LPHD cases selected for CGH studies are summarized in Table 1. The study comprised 17 males and 2 females ranging in age from 10 to 74 years (median, 37). All 18 patients with available clinical data showed involvement of peripheral lymph nodes. Patients were treated either with radiotherapy or chemotherapy, and for 16 (2 are still in therapy) complete remission was obtained. Three patients (3, 15, and 18) had a diffuse large B-cell lymphoma (DLBCL) developed after, respectively, 59, 248, and 126 months from the primary diagnosis of LPHD. Two patients (11 and 15) died of a disease-related cause after 202 and 248 months, respectively. The material available for cytogenetic and CGH studies was from the time of primary diagnosis (16 cases) or was collected at the time of relapse (3 cases). Cytogenetic analysis was performed in 12 cases and metaphases were obtained in 8. Clonal chromosomal abnormalities, including t(3;22) (q27;q11), were identified in case 9 only. In the remaining cultures, either occasional polyploid cells with complex structural chromosomal aberrations (patient 7), cells with nonclonal chromosomal abnormalities (patient 17), or cells with a normal karyotype (patients 3, 5, 6, 14, and 19) were found. During preparation of this paper, a relapse occurred in patient 14, and cytogenetic analysis of the lymph node showed one abnormal metaphase with numerical and structural aberrations, including a t(3;?;1)(q27;?;q21) of 20 karyotyped cells. This metaphase was subjected to further FISH investigations. CGH based on DOP-PCR-amplified genomic DNA from 4 to 5 microdissected
CD20+ L&H cells was successfully performed in all 19 LPHD
cases. The results are summarized in Figure 1, and an example is
illustrated in Figure 2A,B. In this
series of cases a total of 205 genetic imbalances were detected
with an average of 10.8 imbalances per case (range from 3 to 22). Gains
of chromosomal material were more frequent than losses (138 gains [7.3
per tumor] versus 67 losses [3.5 per tumor]). Imbalances were
seen in all chromosomes but Y, which was not analyzed. Chromosomes
19 and 22 should be regarded critically and were finally excluded
(discussed in "Patients, materials and methods"). Less involved
were chromosomes 14, 15, and 21, showing 2 or 3 imbalances each,
whereas all other chromosomes showed 6 or more changes. Gain/loss
dislocations of short and long arm of single chromosomes found in cases
9 and 15 suggest the formation of isochromosomes.
In the present series of LPHD, 3 cytogenetic subgroups could be
constructed: a first group with mainly chromosomal gains (7 cases), a second with a balanced number of gains and losses (8 cases), and a third subgroup showing 17 and more genomic changes (4 cases) (Table 2). The 2 children (ages 10 and 11) were among the latter subgroup.
In this series, a recurrent gain of genetic material from 18 chromosomes was observed. Genomic regions that were overrepresented in more than 36% of the studied cases included partial 1p (36.8%), 1q (57.9%), 2q (36.8%), 3p (52.6%), 3q (47.4%), 4q (47.4%), 5q (52.6%), 6p (36.8%), 6q (47.4%), 8q (47.4%), 11q (36.8%), 12q (42.1%), Xp (57.9%), and Xq (68.4%). The smallest commonly overrepresented regions involve 1p12p22, 1q21q31, 2q24q31, 3p13p21, 3q12q13, 4q12q25, 5q23, 6p, 6q12q24, 8q21, 11q12q22, 12q12, 12q14q15, Xp, and Xq23q26. High-level amplifications of the long arm of chromosome 1 and chromosome 13 were detected in cases 2 and 15, respectively. Case 19 showed amplifications of 5p14, 6q22, and Xp21 (Figure 2B). Recurrent chromosomal losses of 17 chromosomes were detected. Most frequently lost were chromosome 17p/17 (42.1%/36.8%), followed by the loss of 11q (26.3%), 16p (26.3%), 6p (21.1%), 8p (21.1%), and 10p (21.1%). Losses of chromosomes 19 (42%) and 22q (26%) were recurrently seen; however, they were excluded from final calculation for reasons mentioned in "Patients, materials, and methods." The reliability of the CGH results was evaluated in 6 cases (1, 2, 4, 6, 9, and 10) by FISH performed on previously CD20 immunostained frozen
sections. In these cases, centromeric probes for the imbalanced chromosomes 3 (p The reliability of CGH has also been proven by the finding of the same genomic imbalances detected in 2 consecutive lymph node biopsy specimens coming from the first and the second relapse (4 years later) in case 11 (11a and 11b; Table 1). These findings also indicated persistence of the malignant clone during the course of the disease. CGH results are also supported by the very recent cytogenetic data in case 14 obtained 7 years after the diagnosis of LPHD. The only abnormal polyploid cell identified in this material probably representing the malignant cell clone, showed similar imbalances as detected by CGH from tissue taken at the time of diagnosis (gain of X and 1q, and loss of 4p15, 6p, 7p11, and 18; Table 1). CGH analysis performed in case 9 detected all genomic imbalances
previously identified by cytogenetics [loss of 1p and gain of 1q due
to the idic(1)(q10), monosomy 4 and 17, partial loss of chromosome 10 probably because of der(7)t(7;10)(q36;q11)]. In addition some other
aberrations were found (gain of 5q, 6, 20p, partial Xq, and loss of
partial Xp). To clarify some of these findings, we performed
interphase-FISH analysis with centromeric probes for chromosomes 6 (gained) and 1 (control) on available cytogenetic fixed cells.
Malignant cells were identified by 3 cent-1 signals, due to the
idic(1)(q10). By this approach, we detected 2 subpopulations of
malignant cells with either 2 or 3 cent-6 signals (Figure 2D). These
results indicate that at least some of these imbalances not found by
cytogenetics represent subclonal aberrations missed during the banding
analysis. The karyotype of this case was also characterized by the
t(3;22)(q27;q11). This translocation has been additionally analyzed by
metaphase- and interphase-FISH by using a BCL6 probe. In the
only abnormal metaphase found in the FISH experiment, the cosB5-2 probe
hybridized with the normal chromosome 3, der(3) and der(22) indicating
a rearrangement of the BCL6 gene (Figure 2E). This finding
was confirmed by FISH analysis of 20 neoplastic interphase cells,
which, as before, were identified by one normal and one double cent-1
signal because of the idic(1)(q10). Neither rearrangement of
BCL6 nor IgH/
Genetic and molecular aspects of HD are still poorly understood and until now no (cyto)genetic marker(s) specific for HD could be identified. The use of molecular cytogenetic techniques in recent studies of HD, however, allowed difficulties caused by the rare occurrence and low proliferation index of RS cells to be overcome. With FISH combined with CD30 immunostaining, clonal occurrence of numerical chromosome changes in HD have been demonstrated.38 By this approach, however, only limited information restricted to the applied probes was obtained. Another molecular cytogenetic technique that allows the detection of genomic abnormalities in tumor cells without the need of dividing cells is CGH. However, it requires the presence of approximately 50% of neoplastic cells in the analyzed tumor lesion. To overcome this obstacle, in our CGH studies of LPHD we microdissected 4 to 5 single neoplastic cells and applied DOP-PCR for DNA amplification. This combined approach allowed us to study genomic imbalances in selected "popcorn" cells usually not contaminated with normal bystander cells. The reliability of this method was confirmed by several control experiments and additional investigations. By using this strategy, we investigated 19 LPHD cases that showed typical histopathologic and clinical features of this entity. By CGH, genomic imbalances were detected in all cases, including those in which a normal karyotype was found by conventional cytogenetics. The high number of CGH-detected chromosomal imbalances per case (range from 3 to 22; average, 10.8) affecting all evaluated chromosomes suggests the occurrence of very complex chromosomal aberrations in most of the LPHD cases. No correlation between cytogenetic subgroups (Table 2) and clinical features could be established. The majority of detected genomic aberrations in LPHD was recurrent and appeared in a significant number of cases. The most frequent genomic imbalances found in 36.8% to 68.4% of the cases consisted of gains of chromosomes 1p, 1q, 2q, 3p, 3q, 4q, 5q, 6p, 6q, 8q, 11q, 12q, and X, and losses of chromosome 17/17p. Some of these, such as overrepresentation of 1q, 3q, 8q, 12q, X, and loss of 17p, have been frequently observed in various subtypes of NHL, and therefore may be regarded as secondary chromosomal changes associated with disease progression.39 We did, however, detect other recurrent imbalances such as gain of 2q, 4q, 5q, 6, and 11q, which are infrequent in lymphomas and other hematologic malignancies40,41 and therefore might be characteristic for LPHD. Particularly noteworthy is the frequent gain of 6q (47.4%), a chromosome arm typically deleted in NHL, in which 2 putative lymphoma-related tumor suppressor genes (TSGs) have been mapped.28,42,43 Our results suggest that chromosome 6q also carries gene(s) associated with the pathogenesis of LPHD. In this context, the finding of high-level amplification of the 6q22 region detected in case 19 is interesting. The only known candidate gene located in the amplified 6q22 region is the ROS1 oncogene, overexpressed in glioblastoma.44 Its association with hematologic malignancies, however, has not been demonstrated until now. The 9p23-24 amplification that was detected in the only LPHD case analyzed by CGH by Joos et al23 has not been found in our series of LPHD. It is also noteworthy that the pattern of genomic imbalances found by us in LPHD is distinct from the patterns detected in classical HD cases by Ohshima et al22 and Joos et al23 This additionally illustrates a distinction of both subentities of HD. Some other observations made in this study require additional comments. One of them is the high number of genomic imbalances per case (10.8). It contrasts with a relatively low number of genomic imbalances identified in other lymphoma subtypes (eg, average 2.5 imbalances per cell in marginal zone lymphoma [MZL],36 5.8 in mantle cell lymphoma [MCL],45 2.2 to 3 in DLBCL,46,47 and 4.4 in classical HD23). Therefore, our CGH results raise the question whether analyzed cells represented a monoclonal population characterized by a high number of genomic imbalances or a polyclonal/oligoclonal population with aberrations pooled together during the micromanipulation procedure. The latter possibility, however, becomes unlikely, as identical CGH profiles were found in 2 different samples from the same biopsy specimen (patient 9), in 5 as well as 20 cells from the same biopsy specimen (patient 18), and in samples derived from 2 consecutive lymph node biopsy specimens from the same patient (patient 11). Moreover, most of the genomic imbalances found at the time of diagnosis in case 14 have been confirmed by cytogenetic analysis performed 7 years later (14). Genomic complexity found in our series of LPHD seems to be a common feature of HD, as it was found in many published karyotypes of HD cases and HD-derived cell lines17,48 and in one of 2 very recently reported CGH studies of classical HD.22,23 Thus, the high number of genetic imbalances in LPHD cases indicates that the clinical manifestation of this disorder is usually preceded by an accumulation of multiple genetic errors, including gains, losses, and amplifications of chromosomal material. According to a recent hypothesis, HD originates from B cells that have resided in a germinal center for an abnormally long period marked by a high load of acquired immunoglobulin variable heavy-chain gene mutations.11 Simultaneously, an accumulation of complex genomic aberrations preceding the clinical manifestation of this disorder might occur. Another comment concerns the frequent loss of the chromosome 17p/17 detected in 8/7 analyzed LPHD cases. Deletion of 17p has been traditionally associated with the involvement of p53, which is commonly inactivated in human tumors. Nonrandom loss of 17p was also observed in DLBCL,49-51 MCL,52 small lymphocytic lymphoma (SLL),53 and multiple myeloma.54 In contrast to solid tumors, however, mutations and/or deletions of p53/17p occur in a minor fraction of NHL cases, but if present, they usually hallmark a poor prognosis. Taking into consideration the indolent clinical course of the reported cases, a significantly higher incidence of 17/17p losses in LPHD in comparison with other NHL,55 and the absence of p53 immunostaining in studied LPHD cases,56 it is possible that the 17/17p losses in LPHD did not target p53 but another gene located on chromosome 17. Such a putative tumor suppressor gene at 17p has been recently hypothesized by Phillips et al,57 Sankar et al,58 and Fioretos et al.59 Interestingly, lack of p53 mutations has been detected in 8 classical HD cases studied on single RS cells.60 High-level amplifications of genomic sequences have been identified in 3 cases in this study. One showed amplifications of 3 regions, including 5p14, 6q22, and Xp21. Two other LPHD cases revealed an amplification of 1q and chromosome 13. Interestingly, similar amplifications have been previously observed in DLBCL cases reported by Rao et al46 and Monni et al.47 In contrast to DLBCL and other NHL studied by CGH, neither 8q24/CMYC nor 18q21/BCL2 amplification have been detected in our series of LPHD. To complement the CGH investigations, we performed additional FISH
studies of the t(3;22)(q27;q11) and t(3;?;1)(q27;?;q21) identified by
banding analysis in cases 9 and 14, respectively, that led to the
demonstration of the BCL6 rearrangement. Chromosomal translocations involving the 3q27 region have been already recognized as B-NHL-related abnormalities occurring in approximately 40% of
DLBCL and in 5% to 10% of follicular lymphomas.61,62 The t(3q27) results in a deregulation of the BCL6
proto-oncogene, encoding a zinc finger transcription repressor either
by the Ig gene clusters at 2p12, 14q32, and 22q11, or by a
variety of other genomic loci.63-65 It has been shown that
the BCL6 protein is expressed predominantly in normal GC B cells and
related lymphomas, and is required for GC formation and
function.60,66 Interestingly, LPHD cases consistently show
expression of the BCL6 protein and lack expression of Syndecan-1 (a
post-GC B-cell marker), reflecting their GC B-cell origin, whereas most
of the classical HD cases reveal the post-GC phenotype
(BCL6 In summary, by using single microdissected cells-CGH, we studied genomic imbalances in 19 LPHD cases, the largest series of LPHD investigated by molecular cytogenetic techniques until now. The obtained results indicate a consistent occurrence of complex genomic aberrations in "popcorn" cells with a defined profile of recurrent chromosomal gains and losses. The high number of detected imbalances per case involving almost all chromosomes indicates a high complexity of LPHD karyotypes. Although some of the detected imbalances have been recurrently observed in different NHL subtypes, others, such as the gain of 2q, 4q, 5q, 6, and 11q, seem to be associated specifically with LPHD. A search for the involved genes located in these chromosomal regions can potentially shed light on the molecular pathogenesis of LPHD. Further studies are also required to determine an association between the 3q27/BCL6 rearrangement found in 2 of the presented cases and the development of LPHD.
We gratefully acknowledge Prof Benoit from the University of Gent, Dr de Ruysscher from Duffel, and Dr Uyttebroeck and Dr Thomas from the University of Leuven for providing clinical data of some of the patients. Thanks are due to Prof H. Van den Berghe for critically reading the manuscript. We thank E. van Dessel and U. Pluys for their excellent technical assistance and R. Logist for secretarial assistance.
Submitted July 5, 2000; accepted November 10, 2000.
Supported by grants G025298 and G011298 from the FWO (Fund for Scientific Research-Flanders [Belgium]). P.V. is a postdoctoral researcher of the FWO.
This text presents research results of the Belgian program of Interuniversity Poles of attraction initiated by the Belgian State, Prime Minister's Office, Science Policy Programming. The scientific responsibility is assumed by the authors.
A.H. and C.D.W.-P. share senior authorship.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Anne Hagemeijer, Center for Human Genetics-University of Leuven, Campus Gasthuisberg O&N6, Herestraat 49, B-3000 Leuven, Belgium; email: anne.hagemeijer{at}med.kuleuven.ac.be.
1.
Harris NL, Jaffe ES, Stein H, et al.
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
Blood.
1994;84:1361-1392
2.
Pinkus GS, Said JW.
Hodgkin's disease, lymphocyte predominance type, nodular
3.
Wachi E, Nakamura N, Abe M, Wakasa H.
Hodgkin's disease with CD 20 (B1) positive Reed-Sternberg cells 4. Mason DY, Banks PM, Chan J, et al. Nodular lymphocyte predominance Hodgkin's disease: a distinct clinicopathological entity. Am J Surg Pathol. 1994;18:526-530[Medline] [Order article via Infotrieve]. 5. Kuppers R, Roers A, Kanzler H. Molecular single cell studies of normal and transformed lymphocytes. Cancer Surv. 1997;30:45-58[Medline] [Order article via Infotrieve].
6.
Braeuninger A, Kuppers R, Strickler JG, Wacker HH, Rajewsky K, Hansmann ML.
Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B.
Proc Natl Acad Sci U S A.
1997;94:9337-9342
7.
Ohno T, Stribley JA, Wu G, Hinrichs SH, Weisenburger DD, Chan WC.
Clonality in nodular lymphocyte-predominant Hodgkin's disease.
N Engl J Med.
1997;337:459-465
8.
Marafioti T, Hummel M, Anagnostopoulos I, et al.
Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells.
N Engl J Med.
1997;337:453-458
9.
Brauninger A, Hansmann ML, Strickler JG, et al.
Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma.
N Engl J Med.
1999;340:1239-1247
10.
Marafioti T, Hummel M, Anagnostopoulos I, Foss HD, Huhn D, Stein H.
Classical Hodgkin's disease and follicular lymphoma originating from the same germinal center B cell.
J Clin Oncol.
1999;17:3804-3809
11.
Marafioti T, Hummel M, Foss HD, et al.
Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription.
Blood.
2000;95:1443-1450
12.
Delabie J, Tierens A, Wu G, Weisenburger DD, Chan WC.
Lymphocyte predominance Hodgkin's disease: lineage and clonality determination using a single-cell assay.
Blood.
1994;84:3291-3298 13. Ohshima K, Suzumiya J, Mukai Y, et al. Classical Hodgkin and Reed-Sternberg cells demonstrate a nonclonal immature B lymphoid lineage: evidence from a single cell assay and in situ hybridization. Hematol Oncol. 1996;14:123-136[CrossRef][Medline] [Order article via Infotrieve].
14.
Hummel M, Ziemann K, Lammert H, Pileri S, Sabattini E, Stein H.
Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells.
N Engl J Med.
1995;333:901-906 15. Chan WC. Cellular origin of nodular lymphocyte-predominant Hodgkin's lymphoma: immunophenotypic and molecular studies. Semin Hematol. 1999;36:242-252[Medline] [Order article via Infotrieve]. 16. Kumar S, Fend F, Quintanilla-Martinez L, et al. Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease: association with inflammatory bowel disease and immunosuppression. Am J Surg Pathol. 2000;24:66-73[CrossRef][Medline] [Order article via Infotrieve].
17.
Falzetti D, Crescenzi B, Matteuci C, et al.
Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin's disease.
Haematologica.
1999;84:298-305 18. Pedersen RK, Sorensen AG, Pedersen NT, Schmidt KG, Kerndrup GB. Chromosome aberrations in adult Hodgkin disease in a Danish population-based study. Cancer Genet Cytogenet. 1999;110:128-132[CrossRef][Medline] [Order article via Infotrieve]. 19. Weber-Matthiesen K, Winkemann M, Muller-Hermelink A, Schlegelberger B, Grote W. Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to the characterization of tumor cells. J Histochem Cytochem. 1992;40:171-175[Abstract].
20.
Inghirami G, Macri L, Rosati S, Zhu BY, Yee HT, Knowles DM.
The Reed-Sternberg cells of Hodgkin disease are clonal.
Proc Natl Acad Sci U S A.
1994;91:9842-9846 21. Nolte M, Werner M, von Wasielewski R, Nietgen G, Wilkens L, Georgii A. Detection of numerical karyotype changes in the giant cells of Hodgkin's lymphomas by a combination of FISH and immunohistochemistry applied to paraffin sections. Histochem Cell Biol. 1996;105:401-404[CrossRef][Medline] [Order article via Infotrieve]. 22. Ohshima K, Ishiguro M, Ohgami A, et al. Genetic analysis of sorted Hodgkin and Reed-Sternberg cells using comparative genomic hybridization. Int J Cancer. 1999;82:250-255[CrossRef][Medline] [Order article via Infotrieve].
23.
Joos S, Kupper M, Ohl S, et al.
Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells.
Cancer Res.
2000;60:549-552 24. Ohshima K, Kikuchi M, Shibata T, et al. Clonal analysis of Hodgkin's disease shows absence of TCR/Ig gene rearrangement, compared with T-cell-rich B-cell lymphoma and incipient adult T-cell leukemia/lymphoma. Leuk Lymphoma. 1994;15:469-479[Medline] [Order article via Infotrieve].
25.
Gravel S, Delsol G, Al Saati T.
Single-cell analysis of the t(14;18)(q32;q21) chromosomal translocation in Hodgkin's disease demonstrates the absence of this translocation in neoplastic Hodgkin and Reed-Sternberg cells.
Blood.
1998;91:2866-2874 26. Hansmann ML, Godde-Salz E, Hui PK, Muller-Hermelink HK, Lennert K. Cytogenetic findings in nodular paragranuloma (Hodgkin's disease with lymphocytic predominance; nodular) and in progressively transformed germinal centers. Cancer Genet Cytogenet. 1986;21:319-325[CrossRef][Medline] [Order article via Infotrieve]. 27. Slavutsky I, de Vinuesa ML, Estevez ME, Sen L, de Salum SB. Cytogenetic and immunologic phenotype findings in Hodgkin's disease. Cancer Genet Cytogenet. 1985;16:123-130[CrossRef][Medline] [Order article via Infotrieve]. 28. Parsa NZ, Gaidano G, Mukherjee AB, et al. Cytogenetic and molecular analysis of 6q deletions in Burkitt's lymphoma cell lines. Genes Chromosomes Cancer. 1994;9:13-18[Medline] [Order article via Infotrieve]. 29. Kristoffersson U, Heim S, Mandahl N, et al. Prognostic implication of cytogenetic findings in 106 patients with non-Hodgkin lymphoma. Cancer Genet Cytogenet. 1987;25:55-64[CrossRef][Medline] [Order article via Infotrieve]. 30. Koduru PR, Offit K, Filippa DA, Lieberman PH, Jhanwar SC. Cytogenetic and molecular genetic analysis of abnormal cells in Hodgkin's disease. Cancer Genet Cytogenet. 1989;43:109-118[CrossRef][Medline] [Order article via Infotrieve]. 31. Reeves BR, Nash R, Lawler SD, Fisher C, Treleaven JG, Wiltshaw E. Serial cytogenetic studies showing persistence of original clone in Hodgkin's disease. Cancer Genet Cytogenet. 1990;50:1-8[CrossRef][Medline] [Order article via Infotrieve]. 32. Mitelman F. ISCN 1995: an international system for human cytogenetic nomenclature (1995). Basel, Switzerland: Karger; 1995. 33. Kuukasjarvi T, Tanner M, Pennanen S, Karhu R, Visakorpi T, Isola J. Optimizing DOP-PCR for universal amplification of small DNA samples in comparative genomic hybridization. Genes Chromosomes Cancer. 1997;18:94-101[CrossRef][Medline] [Order article via Infotrieve].
34.
Kallioniemi A, Kallioniemi OP, Sudar D, et al.
Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors.
Science.
1992;258:818-821 35. Kallioniemi OP, Kallioniemi A, Piper J, et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer. 1994;10:231-243[Medline] [Order article via Infotrieve]. 36. Dierlamm J, Rosenberg C, Stul M, et al. Characteristic pattern of chromosomal gains and losses in marginal zone B cell lymphoma detected by comparative genomic hybridization. Leukemia. 1997;11:747-758[CrossRef][Medline] [Order article via Infotrieve]. 37. Dierlamm J, Michaux L, Wlodarska I, et al. Trisomy 3 in marginal zone B-cell lymphoma: a study based on cytogenetic analysis and fluorescence in situ hybridization. Br J Haematol. 1996;93:242-249[CrossRef][Medline] [Order article via Infotrieve].
38.
Weber-Matthiesen K, Deerberg J, Poetsch M, Grote W, Schlegelberger B.
Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin's disease.
Blood.
1995;86:1464-1468
39.
Johansson B, Mertens F, Mitelman F.
Cytogenetic evolution patterns in non-Hodgkin's lymphoma.
Blood.
1995;86:3905-3914 40. Knuutila S, Bjorkqvist AM, Autio K, et al. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol. 1998;152:1107-1123[Abstract].
41.
Knuutila S, Aalto Y, Autio K, et al.
DNA copy number losses in human neoplasms.
Am J Pathol.
1999;155:683-694
42.
Gaidano G, Hauptschein RS, Parsa NZ, et al.
Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma.
Blood.
1992;80:1781-1787 43. Zhang Y, Matthiesen P, Harder S, et al. A 3-cM commonly deleted region in 6q21 in leukemias and lymphomas delineated by fluorescence in situ hybridization. Genes Chromosomes Cancer. 2000;27:52-58[CrossRef][Medline] [Order article via Infotrieve].
44.
Birchmeier C, Sharma S, Wigler M.
Expression and rearrangement of the ROS1 gene in human glioblastoma cells.
Proc Natl Acad Sci U S A.
1987;84:9270-9274
45.
Bea S, Ribas M, Hernandez JM, et al.
Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants.
Blood.
1999;93:4365-4374
46.
Rao PH, Houldsworth J, Dyomina K, et al.
Chromosomal and gene amplification in diffuse large B-cell lymphoma.
Blood.
1998;92:234-240
47.
Monni O, Joensuu H, Franssila K, Knuutila S.
DNA copy number changes in diffuse large B-cell lymphoma
48.
Wolf J, Kapp U, Bohlen H, et al.
Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells.
Blood.
1996;87:3418-3428
49.
Cabanillas F, Pathak S, Trujillo J, et al.
Frequent nonrandom chromosome abnormalities in 27 patients with untreated large cell lymphoma and immunoblastic lymphoma.
Cancer Res.
1988;48:5557-5564
50.
Rickert CH, Dockhorn-Dworniczak B, Simon R, Paulus W.
Chromosomal imbalances in primary lymphomas of the central nervous system.
Am J Pathol.
1999;155:1445-1451 51. Jerkeman M, Johansson B, Akerman M, Cavallin-Stahl E, Kristoffersson U, Mitelman F. Prognostic implications of cytogenetic aberrations in diffuse large B-cell lymphomas. Eur J Haematol. 1999;62:184-190[Medline] [Order article via Infotrieve].
52.
Cuneo A, Bigoni R, Rigolin GM, et al.
Cytogenetic profile of lymphoma of follicle mantle lineage: correlation with clinicobiologic features.
Blood.
1999;93:1372-1380 53. Callet-Bauchu E, Salles G, Gazzo S, et al. Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: frequent occurrence of dicentric rearrangements and possible association with adverse outcome. Leukemia. 1999;13:460-468[CrossRef][Medline] [Order article via Infotrieve].
54.
Drach J, Ackermann J, Fritz E, Kromer E, et al.
Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.
Blood.
1998;92:802-809 55. Rodriguez MA, Ford RJ, Goodacre A, Selvanayagam P, Cabanillas F, Deisseroth AB. Chromosome 17- and p53 changes in lymphoma. Br J Haematol. 1991;79:575-582[Medline] [Order article via Infotrieve]. 56. Gupta RK, Norton AJ, Thompson IW, Lister TA, Bodmer JG. p53 expression in Reed-Sternberg cells of Hodgkin's disease. Br J Cancer. 1992;66:649-652[Medline] [Order article via Infotrieve].
57.
Phillips NJ, Ziegler MR, Radford DM, et al.
Allelic deletion on chromosome 17p13.3 in early ovarian cancer.
Cancer Res.
1996;56:606-611 58. Sankar M, Tanaka K, Kumaravel TS, et al. Identification of a commonly deleted region at 17p13.3 in leukemia and lymphoma associated with 17p abnormality. Leukemia. 1998;12:510-516[CrossRef][Medline] [Order article via Infotrieve].
59.
Fioretos T, Strombeck B, Sandberg T, et al.
Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations.
Blood.
1999;94:225-232
60.
Montesinos-Rongen M, Roers A, Kuppers R, Rajewsky K, Hansmann ML.
Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease.
Blood.
1999;94:1755-1760 61. Pescarmona E, De Sanctis V, Pistilli A, et al. Pathogenetic and clinical implications of Bcl-6 and Bcl-2 gene configuration in nodal diffuse large B-cell lymphomas. J Pathol. 1997;183:281-286[CrossRef][Medline] [Order article via Infotrieve]. 62. Chen W, Butler M, Rao PH, et al. The t(2;3)(q21;q27) translocation in non-Hodgkin's lymphoma displays BCL6 mutations in the 5' regulatory region and chromosomal breakpoints distant from the gene. Oncogene. 1998;17:1717-1722[CrossRef][Medline] [Order article via Infotrieve].
63.
Chang CC, Ye BH, Chaganti RS, Dalla-Favera R.
BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor.
Proc Natl Acad Sci U S A.
1996;93:6947-6952
64.
Ye BH, Rao PH, Chaganti RS, Dalla-Favera R.
Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma.
Cancer Res.
1993;53:2732-2735 65. Ohshima A, Miura I, Hashimoto K, et al. Rearrangements of the BCL6 gene and chromosome aberrations affecting 3q27 in 54 patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1997;27:329-334[Medline] [Order article via Infotrieve].
66.
Carbone A, Gloghini A, Gaidano G, et al.
Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease.
Blood.
1998;92:2220-2228
67.
Falini B, Bigerna B, Pasqualucci L, et al.
Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease.
Blood.
1996;87:465-471 68. Liang R, Chan WP, Chan AC, Ho FC. Rearrangement of the bcl-6 gene in Hodgkin's disease, lymphocyte predominant type [letter]. Am J Hematol. 1996;52:63-64[CrossRef][Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  V. Brune, E. Tiacci, I. Pfeil, C. Doring, S. Eckerle, C. J.M. van Noesel, W. Klapper, B. Falini, A. von Heydebreck, D. Metzler, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis J. Exp. Med., September 29, 2008; 205(10): 2251 - 2268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mottok, C. Renne, K. Willenbrock, M.-L. Hansmann, and A. Brauninger Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6 Blood, November 1, 2007; 110(9): 3387 - 3390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Renne, J. I. Martin-Subero, M.-L. Hansmann, and R. Siebert Molecular Cytogenetic Analyses of Immunoglobulin Loci in Nodular Lymphocyte Predominant Hodgkin's Lymphoma Reveal a Recurrent IGH-BCL6 Juxtaposition J. Mol. Diagn., August 1, 2005; 7(3): 352 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Modiano, M. Breen, R. C. Burnett, H. G. Parker, S. Inusah, R. Thomas, P. R. Avery, K. Lindblad-Toh, E. A. Ostrander, G. C. Cutter, et al. Distinct B-Cell and T-Cell Lymphoproliferative Disease Prevalence among Dog Breeds Indicates Heritable Risk Cancer Res., July 1, 2005; 65(13): 5654 - 5661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Katzenberger, G. Ott, T. Klein, J. Kalla, H. K. Muller-Hermelink, and M. M. Ott Cytogenetic Alterations Affecting BCL6 Are Predominantly Found in Follicular Lymphomas Grade 3B with a Diffuse Large B-Cell Component Am. J. Pathol., August 1, 2004; 165(2): 481 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Wlodarska, P. Nooyen, B. Maes, J. I. Martin-Subero, R. Siebert, P. Pauwels, C. De Wolf-Peeters, and A. Hagemeijer Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma Blood, January 15, 2003; 101(2): 706 - 710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Franke, I. Wlodarska, B. Maes, P. Vandenberghe, R. Achten, A. Hagemeijer, and C. De Wolf-Peeters Comparative Genomic Hybridization Pattern Distinguishes T-Cell/Histiocyte-Rich B-Cell Lymphoma from Nodular Lymphocyte Predominance Hodgkin's Lymphoma Am. J. Pathol., November 1, 2002; 161(5): 1861 - 1867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Joos, C. K. Menz, G. Wrobel, R. Siebert, S. Gesk, S. Ohl, G. Mechtersheimer, L. Trumper, P. Moller, P. Lichter, et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2 Blood, February 15, 2002; 99(4): 1381 - 1387. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
3.5), 6 (D6Z1), 16 (D16Z1), and 17 (D17Z1) were applied together with a control probe for one of the unaffected chromosomes (1, 6, 7, 16, or 17). An example is shown in Figure 
/
was detected by Southern
blot analysis performed in this case (data not shown), what can be
explained by the low frequency of malignant cells in analyzed tissue.
Analogous FISH study with cosB2-5 was performed in case 14 on the only
abnormal cell identified by cytogenetics in the recent lymph node
biopsy. Split of signals on the der(3)t(3;?;1)(q27;?;q21) (Figure 
/syn-1+).
further evidence for a B cell derivation: L & H variants of Reed-Sternberg cells express L26, a pan B cell marker.
Am J Pathol.
1988;133:211-217